ASSOCIATION OF THYROID HORMONES AND AUTOIMMUNE THYROIDITIS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA
(Abstract release date: 05/21/15)
EHA Library. Lekka A. 06/12/15; 102592; PB1842
Antigoni Lekka
Contributions
Contributions
Abstract
Abstract: PB1842
Type: Publication Only
Background
Thyroid disease has been associated with increased incidence of leukemia, myelodysplastic syndrome (MDS) and lymphoma. No previous study has investigated whether thyroid disease and especially autoimmune thyroid disease (ATD) is associated with chronic myelomonocytic leukemia (CMML), a hematologic malignancy which has been classified as a subtype of MDS but was recently demonstrated to be a distinct entity combining proliferative and dysplastic features.
Aims
Methods
Our study included 14 cases with incident histologically confirmed CMML and 70 controls (one patient versus five controls) who came for an annual check-up examination without any neoplastic and infectious conditions, matched on gender, age and year/month of diagnosis (±1 month) between 2004-2012. All participants were submitted to clinical and ultrasound thyroid evaluation. Informed consent was obtained from all study participants. Serum free T3 (fT3), free T4 (fT4), thyroid-stimulating hormone (TSH), thyroglobulin and thyroperoxidase antibodies (anti-TG and anti-TPO) were determined using electrochemiluminescence on Cobas e411 analyzer (Roche, Basel, Switzerland). The statistical analysis of the data was performed using IBM-SPSS® version 22 for Windows.
Results
Mean serum levels of fT3 and fT4 were significantly higher in CMML patients than in controls ( fT3 in patients with CMML: 3.6 ± 0.3 pg/mL versus controls: 2.9 ± 0.42 pg/mL, p<0.001; fT4 in patients with CMML: 1.7 ± 0.29 ng/dL versus controls: 1.4 ± 0.28 ng/dL, p<0.001). The prevalence of anti-thyroid antibodies (anti-TG and anti-TPO Ab) was significantly higher in CMML patients than in controls (p<0.001). On the contrary, mean TSH serum levels were significantly lower in CMML patients than in controls (TSH in patients with CMML: 1.56 ± 0.6 μΙU/mL versus controls: 2.9 ± 0.4 μIU/mL, p=0.001). The frequency of family history of thyroid disease (first degree relatives) in CMML patients was similar with that reported by controls (p=0.52). Finally, the prevalence of clinical thyroid disease-especially ATD-was higher in patients with CMML than in controls (p=0.06, though not statistically significant at α=0.05).
Summary
We have found biologically plausible and empirically strong evidence that thyroid hormones, thyroid disease and especially ATD may be associated with CMML. Further larger prospective studies are needed to confirm this association and explore underlying interactive mechanisms between thyroid hormones and thyroid autoimmunity with myelopoiesis and leukemogenesis.
Keyword(s): Chronic myelomonocytic leukemia, Myeloproliferative disorder
Type: Publication Only
Background
Thyroid disease has been associated with increased incidence of leukemia, myelodysplastic syndrome (MDS) and lymphoma. No previous study has investigated whether thyroid disease and especially autoimmune thyroid disease (ATD) is associated with chronic myelomonocytic leukemia (CMML), a hematologic malignancy which has been classified as a subtype of MDS but was recently demonstrated to be a distinct entity combining proliferative and dysplastic features.
Aims
In this case-control study, we investigated the potential association of thyroid hormones and ATD with CMML.
Methods
Our study included 14 cases with incident histologically confirmed CMML and 70 controls (one patient versus five controls) who came for an annual check-up examination without any neoplastic and infectious conditions, matched on gender, age and year/month of diagnosis (±1 month) between 2004-2012. All participants were submitted to clinical and ultrasound thyroid evaluation. Informed consent was obtained from all study participants. Serum free T3 (fT3), free T4 (fT4), thyroid-stimulating hormone (TSH), thyroglobulin and thyroperoxidase antibodies (anti-TG and anti-TPO) were determined using electrochemiluminescence on Cobas e411 analyzer (Roche, Basel, Switzerland). The statistical analysis of the data was performed using IBM-SPSS® version 22 for Windows.
Results
Mean serum levels of fT3 and fT4 were significantly higher in CMML patients than in controls ( fT3 in patients with CMML: 3.6 ± 0.3 pg/mL versus controls: 2.9 ± 0.42 pg/mL, p<0.001; fT4 in patients with CMML: 1.7 ± 0.29 ng/dL versus controls: 1.4 ± 0.28 ng/dL, p<0.001). The prevalence of anti-thyroid antibodies (anti-TG and anti-TPO Ab) was significantly higher in CMML patients than in controls (p<0.001). On the contrary, mean TSH serum levels were significantly lower in CMML patients than in controls (TSH in patients with CMML: 1.56 ± 0.6 μΙU/mL versus controls: 2.9 ± 0.4 μIU/mL, p=0.001). The frequency of family history of thyroid disease (first degree relatives) in CMML patients was similar with that reported by controls (p=0.52). Finally, the prevalence of clinical thyroid disease-especially ATD-was higher in patients with CMML than in controls (p=0.06, though not statistically significant at α=0.05).
Summary
We have found biologically plausible and empirically strong evidence that thyroid hormones, thyroid disease and especially ATD may be associated with CMML. Further larger prospective studies are needed to confirm this association and explore underlying interactive mechanisms between thyroid hormones and thyroid autoimmunity with myelopoiesis and leukemogenesis.
Keyword(s): Chronic myelomonocytic leukemia, Myeloproliferative disorder
Abstract: PB1842
Type: Publication Only
Background
Thyroid disease has been associated with increased incidence of leukemia, myelodysplastic syndrome (MDS) and lymphoma. No previous study has investigated whether thyroid disease and especially autoimmune thyroid disease (ATD) is associated with chronic myelomonocytic leukemia (CMML), a hematologic malignancy which has been classified as a subtype of MDS but was recently demonstrated to be a distinct entity combining proliferative and dysplastic features.
Aims
Methods
Our study included 14 cases with incident histologically confirmed CMML and 70 controls (one patient versus five controls) who came for an annual check-up examination without any neoplastic and infectious conditions, matched on gender, age and year/month of diagnosis (±1 month) between 2004-2012. All participants were submitted to clinical and ultrasound thyroid evaluation. Informed consent was obtained from all study participants. Serum free T3 (fT3), free T4 (fT4), thyroid-stimulating hormone (TSH), thyroglobulin and thyroperoxidase antibodies (anti-TG and anti-TPO) were determined using electrochemiluminescence on Cobas e411 analyzer (Roche, Basel, Switzerland). The statistical analysis of the data was performed using IBM-SPSS® version 22 for Windows.
Results
Mean serum levels of fT3 and fT4 were significantly higher in CMML patients than in controls ( fT3 in patients with CMML: 3.6 ± 0.3 pg/mL versus controls: 2.9 ± 0.42 pg/mL, p<0.001; fT4 in patients with CMML: 1.7 ± 0.29 ng/dL versus controls: 1.4 ± 0.28 ng/dL, p<0.001). The prevalence of anti-thyroid antibodies (anti-TG and anti-TPO Ab) was significantly higher in CMML patients than in controls (p<0.001). On the contrary, mean TSH serum levels were significantly lower in CMML patients than in controls (TSH in patients with CMML: 1.56 ± 0.6 μΙU/mL versus controls: 2.9 ± 0.4 μIU/mL, p=0.001). The frequency of family history of thyroid disease (first degree relatives) in CMML patients was similar with that reported by controls (p=0.52). Finally, the prevalence of clinical thyroid disease-especially ATD-was higher in patients with CMML than in controls (p=0.06, though not statistically significant at α=0.05).
Summary
We have found biologically plausible and empirically strong evidence that thyroid hormones, thyroid disease and especially ATD may be associated with CMML. Further larger prospective studies are needed to confirm this association and explore underlying interactive mechanisms between thyroid hormones and thyroid autoimmunity with myelopoiesis and leukemogenesis.
Keyword(s): Chronic myelomonocytic leukemia, Myeloproliferative disorder
Type: Publication Only
Background
Thyroid disease has been associated with increased incidence of leukemia, myelodysplastic syndrome (MDS) and lymphoma. No previous study has investigated whether thyroid disease and especially autoimmune thyroid disease (ATD) is associated with chronic myelomonocytic leukemia (CMML), a hematologic malignancy which has been classified as a subtype of MDS but was recently demonstrated to be a distinct entity combining proliferative and dysplastic features.
Aims
In this case-control study, we investigated the potential association of thyroid hormones and ATD with CMML.
Methods
Our study included 14 cases with incident histologically confirmed CMML and 70 controls (one patient versus five controls) who came for an annual check-up examination without any neoplastic and infectious conditions, matched on gender, age and year/month of diagnosis (±1 month) between 2004-2012. All participants were submitted to clinical and ultrasound thyroid evaluation. Informed consent was obtained from all study participants. Serum free T3 (fT3), free T4 (fT4), thyroid-stimulating hormone (TSH), thyroglobulin and thyroperoxidase antibodies (anti-TG and anti-TPO) were determined using electrochemiluminescence on Cobas e411 analyzer (Roche, Basel, Switzerland). The statistical analysis of the data was performed using IBM-SPSS® version 22 for Windows.
Results
Mean serum levels of fT3 and fT4 were significantly higher in CMML patients than in controls ( fT3 in patients with CMML: 3.6 ± 0.3 pg/mL versus controls: 2.9 ± 0.42 pg/mL, p<0.001; fT4 in patients with CMML: 1.7 ± 0.29 ng/dL versus controls: 1.4 ± 0.28 ng/dL, p<0.001). The prevalence of anti-thyroid antibodies (anti-TG and anti-TPO Ab) was significantly higher in CMML patients than in controls (p<0.001). On the contrary, mean TSH serum levels were significantly lower in CMML patients than in controls (TSH in patients with CMML: 1.56 ± 0.6 μΙU/mL versus controls: 2.9 ± 0.4 μIU/mL, p=0.001). The frequency of family history of thyroid disease (first degree relatives) in CMML patients was similar with that reported by controls (p=0.52). Finally, the prevalence of clinical thyroid disease-especially ATD-was higher in patients with CMML than in controls (p=0.06, though not statistically significant at α=0.05).
Summary
We have found biologically plausible and empirically strong evidence that thyroid hormones, thyroid disease and especially ATD may be associated with CMML. Further larger prospective studies are needed to confirm this association and explore underlying interactive mechanisms between thyroid hormones and thyroid autoimmunity with myelopoiesis and leukemogenesis.
Keyword(s): Chronic myelomonocytic leukemia, Myeloproliferative disorder
{{ help_message }}
{{filter}}